

[239] MITOCHONDRIAL THERAPY AND AGE-RELATED DISEASES

Natalie Yivgi Ohana^{1, 1} Minovia Therapeutics

- **Investment Rational**

One of the fascinating things about our cells is that they contain hundreds of tiny power plants called mitochondria. During aging and in certain diseases mitochondria are damaged. Minovia develops methods to transplant normal mitochondria in diseased cells. We are currently conducting clinical studies in patients suffering from rare diseases, bringing hope to all mitochondrial diseases, and aging in general.

- **Business Strategy**

Minovia develops a biological platform technology and products based on enhancing cellular energy production. Minovia's products have the potential to treat many pathologic conditions associated with aging. As a strategy, Minovia is presently focusing on a group of rare mitochondrial diseases, affecting mainly children and with no available treatment.

- **Core Technology**

Proprietary technology for the enhancement of energy production by human cells through enrichment with normal and healthy mitochondria. Our lead products are compositions of functional mitochondria isolated from placental cells or white blood cells in a fast and simple process, used fresh or frozen and yielding off-the-shelf therapeutic products.

- **Product Profile/Pipeline**

Our pipeline include rare mitochondrial diseases and mitochondria-related aging disorders. There are several advantages for rare disease markets: faster regulatory track, less money and shorter time to reach market and higher price per treatment. Mitochondrial diseases have a worldwide prevalence of ~1:8000. Based on average price of \$250,000 per patient (orphan drugs) the estimated market potential is >\$2B.

- **What's Next?**

In 2017 Minovia will conduct treatment in 3 patients, as a compassionate treatment and a proof-of-concept for the mitochondrial therapy. Minovia's next mission is to advance pre-clinical studies until that will enable to submit an IND in the US. Leveraging on its platform technology, Minovia will raise funds to expend to additional clinical indications.